A study in JAMA Network Open found that women and individuals with preexisting cardiovascular conditions are more likely to suffer from long COVID, but vaccinations, especially multiple doses, significantly reduce this risk.
Agomab wins FDA orphan drug status for idiopathic pulmonary fibrosis asset – Pharmaceutical Technology
Agomab is now eligible for market exclusivity and a range of financial incentives. Image credit: Shutterstock / HammadKhn. Six months after kicking off a Phase
June 7, 2024